The break trial represents valuable experiment for any GHK-Cu user completing 6+ month treatment course - discontinuing for 2-3 months reveals how well benefits persist, helps determine whether cycling or continuous use better suits individual biology, provides psychological break from rigid routine, and offers cost savings period while assessing necessity of ongoing application
Pharmacokinetic parameters such as AUC, maximum plasma concentration (Cmax), terminal elimination t1/2, volume of distribution (Va), and clearance were calculated [2]
Six controlled trials in approximately 900 participants are summarized in Stier et al
For those focused on early prediction and prevention, these findings reinforce a critical message: interventions must begin in preclinical stages where biological pathways remain modifiable
The NAD connection: sustained NAD availability from NNMT inhibition has downstream effects that are not fully mapped across cell types